NZ519381A - New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders - Google Patents

New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders

Info

Publication number
NZ519381A
NZ519381A NZ519381A NZ51938100A NZ519381A NZ 519381 A NZ519381 A NZ 519381A NZ 519381 A NZ519381 A NZ 519381A NZ 51938100 A NZ51938100 A NZ 51938100A NZ 519381 A NZ519381 A NZ 519381A
Authority
NZ
New Zealand
Prior art keywords
antipsychotic
indol
methyl
dioxino
tetrahydro
Prior art date
Application number
NZ519381A
Other languages
English (en)
Inventor
Karen Lovell Marquis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NZ519381A publication Critical patent/NZ519381A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NZ519381A 1999-12-10 2000-12-07 New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders NZ519381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
PCT/US2000/033060 WO2001041750A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Publications (1)

Publication Number Publication Date
NZ519381A true NZ519381A (en) 2004-04-30

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ519381A NZ519381A (en) 1999-12-10 2000-12-07 New therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders

Country Status (20)

Country Link
EP (1) EP1235570A2 (ru)
JP (1) JP5557409B2 (ru)
KR (1) KR100772854B1 (ru)
CN (1) CN1230164C (ru)
AR (1) AR026756A1 (ru)
AU (1) AU784211B2 (ru)
BR (1) BR0016168A (ru)
CA (1) CA2396351C (ru)
CZ (1) CZ20021880A3 (ru)
EA (1) EA005002B1 (ru)
HK (1) HK1045942A1 (ru)
HU (1) HUP0203309A3 (ru)
IL (2) IL149669A0 (ru)
MX (1) MXPA02005649A (ru)
NO (1) NO20022739L (ru)
NZ (1) NZ519381A (ru)
PL (1) PL355292A1 (ru)
TW (1) TWI222864B (ru)
WO (1) WO2001041750A2 (ru)
ZA (1) ZA200205484B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874767A (zh) 2003-10-29 2006-12-06 惠氏公司 包含aplindore和其衍生物的缓释药物组合物
WO2006089053A2 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
US20110059947A1 (en) * 2008-02-13 2011-03-10 Targacept, Inc. Alpha 7 nicotinic agonists and antipsychotics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
CZ20021880A3 (cs) 2002-08-14
IL149669A (en) 2006-06-11
PL355292A1 (en) 2004-04-05
JP5557409B2 (ja) 2014-07-23
NO20022739D0 (no) 2002-06-07
EP1235570A2 (en) 2002-09-04
IL149669A0 (en) 2002-11-10
ZA200205484B (en) 2003-12-31
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
KR20030016207A (ko) 2003-02-26
WO2001041750A3 (en) 2002-02-14
EA200200656A1 (ru) 2002-12-26
CN1409633A (zh) 2003-04-09
TWI222864B (en) 2004-11-01
WO2001041750A2 (en) 2001-06-14
MXPA02005649A (es) 2004-09-10
CA2396351A1 (en) 2001-06-14
HUP0203309A3 (en) 2004-12-28
CN1230164C (zh) 2005-12-07
HK1045942A1 (zh) 2002-12-20
AU1949001A (en) 2001-06-18
HUP0203309A2 (hu) 2003-01-28
NO20022739L (no) 2002-06-07
AR026756A1 (es) 2003-02-26
BR0016168A (pt) 2002-08-20
JP2003516350A (ja) 2003-05-13
KR100772854B1 (ko) 2007-11-02
EA005002B1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
EP1994932A1 (en) Use of N-desmethylclozapine to treat human psychosis
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
MXPA04007752A (es) Terapia de combinacion para tratamiento de esquizofrenia.
AU780817B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US20070238725A1 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
US6350773B1 (en) Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
CA2649590A1 (en) Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
CA2396351C (en) New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
AU2004246820B2 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
Cheng et al. Dopamine hypothesis
MXPA05013580A (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)